Recently, Xbiome Co. Ltd. (hereinafter referred to as “Xbiome”) and BioMap (Beijing) Intelligent Technology Co., Ltd. (hereinafter referred to as “BioMap”) officially signed a strategic cooperation agreement.Both parties will focus on AI-enabled R&D and innovation in microbial drugs and probiotic products, integrating their respective core strengths in life science foundation models and microbiome technology. They will engage in deep collaboration across four key areas: joint development of technology platforms, co-construction of models, joint market expansion, and synergistic ecosystem talent development. By promoting cross-domain technological integration, they aim to enhance the efficiency of microecological R&D and jointly explore new frontiers in the AI + microbiome industry.
In accordance with the agreement, both parties will build a framework grounded in the establishment of R&D platforms, centered on vertical model training, and oriented toward the implementation of industrial application scenarios.Multi-layered, Full-chainstrategic cooperation framework.
The two parties will focus on Xbiome’s R&D needs for microbial drugs, probiotics, and other products, driving deep synergy between BioMap’s life science foundation large model xTrimo and its dry-wet closed-loop discovery system BioMap OS, and Xbiome’s three core platforms in bioinformatics, microbiology, and molecular biology. Leveraging Xbiome’s high-quality strain library and multi-modal omics data resources, the parties will jointly undertake technical breakthroughs such as automated and intelligent transformation and integration of the DBTL (Design-Build-Test-Learn) dry-wet closed loop; conduct research on the specific mechanisms of action between microbes and hosts; and systematically enhance R&D efficiency and product quality stability. Meanwhile, based on actual R&D and production needs, the two parties will jointly develop customized industry solutions.Providing AI Core Drive for the Design, R&D, and Industrialization of Microorganisms.
In terms of market expansion, both parties will integrate resources in technology, channels, supply chains, and ecosystem partners to jointly expand into three core areas: In the food and dairy sector, leveraging co-developed AI microbial models and automated screening capabilities, they will provide integrated solutions for strain screening, functional validation, and process optimization to major health companies in the probiotic and dairy industries. In the pharmaceutical and healthcare sector, capitalizing on their combined strengths in microbiomics and AI technology, they will offer automated dry-wet integrated AI-driven microbial drug development solutions—from early-stage R&D to in vitro efficacy validation—for pharmaceutical companies and medical institutions. In the scientific research services sector, they will co-establish an AI-plus-scientific computing service system to support scientists from both sides in jointly applying for major research projects at various levels and co-publishing high-impact academic achievements.
This collaboration represents a deep integration of foundational AI technologies with microbiome industry applications, enabling both parties to leverage their complementary strengths to break through the efficiency bottlenecks of traditional microbiome R&D and build“Algorithm + Data + Industry”a complete innovation closed loop,Exploring Replicable New Pathways to Accelerate Technological Iteration and Commercialization in the Microbiome Industry.
Dr. Tan Yan, Co-founder and CEO of XbiomeBioMap is a global leader in foundational large models for life sciences, with its technological prowess and industry vision ranking among the top tier internationally. Xbiome has cultivated deep expertise in the microbiome field for many years, building end-to-end industrial capabilities spanning from basic research and drug development to clinical translation and consumer health. The technical accumulation and resource endowments of both parties are highly complementary. This collaboration will deeply integrate BioMap’s algorithmic and computational advantages, along with its dry-wet closed-loop capabilities, into the entire microbiome R&D process. This is expected to significantly improve strain screening efficiency, deepen the understanding of host-microbe interaction mechanisms, and accelerate intelligent upgrades in production. We look forward to working with BioMap to explore new frontiers in the AI + microbiome industry and deliver high-quality microecological solutions for public health.
Xu Ziyao, Senior Vice President of BioMapXbiome is a leading enterprise in China’s AI-driven microbiome sector, boasting a top-tier interdisciplinary R&D team, extensive microbiomics data resources, and mature capabilities in clinical translation and commercialization. It covers the complete industrial pathway from innovative drugs to general health products. The value of life science AI must ultimately be validated through real-world industrial applications. Xbiome’s deep industry expertise provides highly valuable vertical application scenarios for the xTrimo large model and the BioMap OS platform. We look forward to driving the specialized, scenario-based implementation of foundational life science large models in the microbiome field through deep collaboration with Xbiome, leveraging AI technology to reshape the R&D paradigm for the microecology, accelerate the industrial translation of innovative achievements, and jointly contribute to the high-quality development of China’s biotechnology industry.
About Xbiome
Shenzhen Xbiome Co., Ltd., established in 2017, is an industry-leading AI-driven microbiome research and industrial translation platform. The company has strategically focused on three core areas: fecal microbiota transplantation (FMT), drug discovery, and probiotics. It currently has four drug candidates in clinical development for oncology, gastrointestinal diseases, and immune-related disorders, two of which have advanced to Phase II clinical trials. Its FMT business collaborates with nearly 20 renowned tertiary hospitals across China on multi-indication clinical studies and has launched an AI-FMT personalized precision therapy solution. In the probiotics sector, Xbiome has established commercial partnerships with several leading domestic and international health and wellness companies, continuously advancing the development of proprietary strains and their product commercialization.
As a technological leader in China’s AI microbiome sector, Xbiome has established a full-stack AI technology system for the microecosystem, integrating “data, algorithms, and orchestration” into a unified triad. On the data front, the company has accumulated multimodal human microbiome data covering 26 disease areas, comprising over 42,000 samples with clinical outcomes, and built a core resource library containing 15,000 human-derived bacterial strains. Leveraging clinical cohorts and commercial operations, Xbiome has formed a unique “negative-cost” data accumulation loop, establishing high-value vertical data barriers that general-purpose large models cannot cover. On the algorithm front, its self-developed X-series models span the entire R&D chain, including single-strain metabolic modeling, microbial community ecological analysis, and microbe-host interaction prediction. Among these, the SNE foundational microecosystem large model, trained on 210,000 samples, achieves strong generalization capabilities across cohorts and diseases, with multiple core technologies reaching international leading levels.
Based on this core technology framework, Xbiome is building BiomeOS Intelligent R&D Platform: AI Agents Connect the Full-Chain R&D Tools to Drive “Product Iteration - Data Feedback - Model Upgrade”Dual Flywheel Growth, currently achieving a several-fold efficiency improvement in core R&D processes, continuously empowering pipeline advancement and commercialization.
About BioMap
BioMap is a global leader in foundational large models for life sciences, dedicated to building next-generation AI infrastructure for the life sciences industry to enhance discovery efficiency. BioMap’s independently developed xTrimo, a foundational large model for life sciences with 268 billion parameters, achieves more accurate AI predictions by decoding the underlying principles of genes, proteins, cells, and biological systems. It has achieved state-of-the-art (SOTA) performance in over 300 prediction tasks across more than 20 subfields of life sciences, and has won honors such as the Grand Prize in the inaugural World Virtual Cell Challenge. The company’s BioMap OS, a life science discovery system built on foundational large models, helps users establish systematic AI capabilities. Through AI-driven dry-wet closed-loop discovery, it enables innovative tasks such as data insight generation, parameter optimization, and generative design, while also helping users accumulate their own data and train their own AI models to continuously improve their AI proficiency. Currently, BioMap supports over 800 institutional users worldwide, covering multiple vertical fields including antibodies and novel proteins, innovative therapies and precision medicine, synthetic biology, and cutting-edge scientific research.
-End-